What the April 22 FDA Category 2 Removal Actually Means (and Doesn’t)

April 21, 2026 — one day before the removal takes effect

On April 22, 2026, the FDA will formally remove 12 peptides from its Category 2 “significant safety concerns” list. By the end of day Wednesday, a great deal of coverage — and an enormous amount of social media — will describe this as “legalization.” That framing is wrong. The removal is real. The legalization is not.

This piece explains, precisely, what the April 22 action changes and what it does not.

The 12 Peptides

BPC-157, TB-500 (Thymosin Beta-4 Fragment), Semax, Epitalon, MOTs-C, KPV, DSIP (Emideltide), LL-37 (Cathelicidin), Dihexa, GHK-Cu, PEG-MGF, and Melanotan II — all in both acetate and free base forms.

What Changes on April 22

FDA removes these 12 from Category 2. That is the entire regulatory action.

The mechanism is procedural. The original nominators of the substances voluntarily withdrew their nominations. Under the 503A bulk drug substances evaluation framework, once a nominator withdraws, the FDA removes the entry after a 7-day notice period. April 22 is the end of that notice period for this batch.

The removal was confirmed through the FDA’s 503A Categories document update and analyzed publicly by Orrick, the law firm whose pharmaceutical compounding practice is one of the few authoritative voices working in this space.

What Does Not Change on April 22

None of the following becomes true after the removal takes effect.

These peptides are not approved drugs. None of the 12 has FDA marketing approval for any indication.

*These peptides are not legal for 503A compounding.** Removal from Category 2 is not the same as inclusion on Category 1 — the list of substances that 503A compounding pharmacies may legally use. Category 1 inclusion requires a separate FDA evaluation and action. As Orrick’s analysis states plainly: *”the removal does not authorize compounding — it merely removes the formal ‘significant safety concern’ designation.”

These peptides are not cleared for human use. Human-use clearance comes through approval pathways that the FDA has not applied to any of these 12 substances.

Pharmacies may not compound these for prescriptions. 503A pharmacies are required to use bulk drug substances that are either the subject of an applicable USP or NF monograph, a component of an FDA-approved drug, or on the FDA’s Category 1 list. None of the 12 meets any of those conditions on April 22.

The 2023 restrictions are not reversed. The 2023 Category 2 placement and its practical consequences for legitimate compounding remain in effect in every substantive respect.

Why This Is Still a Signal

Removal from Category 2 is a procedural change, not an approval. But it is a directional signal. It suggests that the political and regulatory posture that placed these peptides on the safety-concerns list in 2023 has shifted. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review seven of the 12 on July 23–24, 2026, and the remaining five before February 2027. Those are the meetings where actual regulatory status could change.

July 23: BPC-157, KPV, MOTs-C, TB-500.
July 24: DSIP, Epitalon, Semax.
Before February 2027: LL-37, Dihexa, GHK-Cu, PEG-MGF, Melanotan II.

A PCAC recommendation is not a final regulatory action either. The advisory committee recommends; the FDA decides. Timelines between recommendation and publication of a revised Category 1 list vary and are not guaranteed.

The Pharmaceutical-Grade Problem

Even if every one of the 12 were added to Category 1 tomorrow, compounding pharmacies could not necessarily produce them. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, has stated publicly that for many of these peptides, no pharmaceutical-grade active ingredient is available. Federal law requires compounded drugs to use pharmaceutical-grade source material. A Category 1 listing without a pharmaceutical-grade supply creates a theoretical permission no legitimate pharmacy can actually use — a gap the gray market has been exploiting for years and that Category 1 reclassification, on its own, would not close.

What This Means Practically

For patients: April 22 changes nothing about access. These peptides are not legally available through a licensed compounding pharmacy today, and they will not be tomorrow.

For clinicians: prescribing options have not expanded. Nothing in the April 22 action changes what is or is not appropriate for your patients.

For 503A and 503B pharmacies: the Category 2 designation has been procedurally lifted, but the Category 1 inclusion required for legitimate compounding has not occurred. Empower Pharmacy has published a response positioning for post-PCAC access and is one of several legitimate compounding operations watching the July meeting closely.

For the research and evidence community: the scientific status of these 12 compounds has not changed. The preclinical evidence portfolios, the thin-to-nonexistent human trial data for most, and the routine misattribution of results across routes and populations — none of it is touched by a regulatory procedural action.

Peptidings’ Position

We cover all 12 of these compounds. Each has an evidence tier, a verdict, a Claims vs. Evidence section, and a Safety section. By the end of the day on April 22, every one of the 12 will have a Legal Status section reflecting the procedural removal, the PCAC review timeline, and — plainly — the fact that the removal does not authorize use.

We built this site for moments like this. When the evidence conversation is about to be overrun by a framing that does not match the facts, our job is to hold the line on the facts. That is what we will be doing on April 22, and the day after, and every day after that.

— Peptidings Editorial
April 21, 2026